Analysis of epidermal growth factor receptor gene T790M mutation in plasmatic ctDNA samples of pa-tients with non-small cell lung cancer
10.3969/j.issn.1006-5725.2017.19.019
- VernacularTitle:非小细胞肺癌患者外周血ctDNA样本中EGFR-T790M基因突变分析
- Author:
Yaxi DU
1
;
Yuhui MA
;
Changshao YANG
;
Lianhua YE
;
Xiaojie DING
;
Quan LI
;
Yinjin GUO
;
Junxi LIU
;
Yunchao HUANG
;
Yongchun ZHOU
Author Information
1. 教育部高原区域性高发肿瘤国际合作联合实验室/云南省肿瘤研究所/云南省肺癌研究重点实验室/昆明市肺癌研究重点实验室
- Keywords:
non-small cell lung cancer;
ctDNA;
T790M mutation;
super ARMS
- From:
The Journal of Practical Medicine
2017;33(19):3228-3232
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate epidermal growth factor receptor(EGFR)gene T790M mutation in plasmatic ctDNA samples from 171 patients with non-small cell lung cancer and analyze the relationship between EGFR T790M mutation and the clinical factors. Methods The EGFR T790M mutation was detected in 171 cases by super amplification refractory mutation system(Super ARMS)in this paper. Rusults The EGFR gene T790M mutation was identified in 7.60%(13/171)plasmatic ctDNA samples which mostly came from patients withⅢb~Ⅳstages of lung cancer. The EGFR T790M mutation rate was identified in 2.05%(3/146)plasmatic samples of pa-tients who did not received treatment of EGFR-TKIs,which was lower than 40.00%(10/25,P<0.05)plasmatic samples of patients who received treatment of first generational EGFR-TKIs. The EGFR T790M mutation rate was identified in 75.00%(3/4) and 60.00%(6/10) plasmatic samples of patients who have received TKI for 6 to 10 months and more than 10 months,which was higher than 9.10%(1/11,P < 0.05)plasmatic samples of patients who have received TKIs for less than 6 months. Conclusions This article demonstrated that EGFRT790M muta-tion was more common in lately NSCLC patients who have received TKIs treatmentover 6 months,meanwhile the EGFR T790M mutation dynamical detective technology will effectively guide the clinic treatment.
